PL2707017T3 - Liksisenatyd i metformina do leczenia cukrzycy typu 2 - Google Patents

Liksisenatyd i metformina do leczenia cukrzycy typu 2

Info

Publication number: PL2707017T3
Authority: PL; Poland
Prior art keywords: lixisenatide; metformin; treatment; diabetes type; diabetes
Prior art date: 2011-05-13

Application number

PL12723132T

Other languages

English (en)

Inventor

Peter Ruus

Louise Silvestre

Patrick Miossec

Jean-Louis Pinquier

Agnes Hincelin-Mery

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-05-13

Filing date

2012-05-11

Publication date

2016-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46148833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2707017(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-05-11 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2016-03-31 Publication of PL2707017T3 publication Critical patent/PL2707017T3/pl

Links

XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 title 1
229960001093 lixisenatide Drugs 0.000 title 1
108010004367 lixisenatide Proteins 0.000 title 1
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title 1
229960003105 metformin Drugs 0.000 title 1
208000001072 type 2 diabetes mellitus Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PL12723132T 2011-05-13 2012-05-11 Liksisenatyd i metformina do leczenia cukrzycy typu 2 PL2707017T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP11166120		2011-05-13
EP12163637		2012-04-10
EP12723132.2A EP2707017B1 (en)	2011-05-13	2012-05-11	Lixisenatide and metformin for treatment of diabetes type 2
PCT/EP2012/058747 WO2012156298A1 (en)	2011-05-13	2012-05-11	Lixisenatide and metformin for treatment of diabetes type 2

Publications (1)

Publication Number	Publication Date
PL2707017T3 true PL2707017T3 (pl)	2016-03-31

Family

ID=46148833

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL12723132T PL2707017T3 (pl)	2011-05-13	2012-05-11	Liksisenatyd i metformina do leczenia cukrzycy typu 2

Country Status (19)

Country	Link
US (1)	US20130065828A1 (pl)
EP (1)	EP2707017B1 (pl)
JP (2)	JP6442284B2 (pl)
KR (1)	KR20140043755A (pl)
CN (2)	CN107693782A (pl)
AU (1)	AU2012257849B2 (pl)
BR (1)	BR112013029062A2 (pl)
CA (1)	CA2835259C (pl)
CY (1)	CY1117250T1 (pl)
DK (1)	DK2707017T3 (pl)
ES (1)	ES2556466T3 (pl)
HR (1)	HRP20151369T1 (pl)
HU (1)	HUE028459T2 (pl)
MX (1)	MX362527B (pl)
PL (1)	PL2707017T3 (pl)
PT (1)	PT2707017E (pl)
RU (1)	RU2623023C2 (pl)
SI (1)	SI2707017T1 (pl)
WO (1)	WO2012156298A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE068164T2 (hu)	2008-10-17	2024-12-28	Sanofi Aventis Deutschland	Egy inzulin és egy GLP-1 agonista kombinációja
CA2780460C (en)	2009-11-13	2018-09-04	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
SG10201500871TA (en)	2009-11-13	2015-04-29	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist and methionine
RS55378B1 (sr)	2010-08-30	2017-03-31	Sanofi Aventis Deutschland	Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
BR112014004726A2 (pt)	2011-08-29	2017-04-04	Sanofi Aventis Deutschland	combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI641381B (zh)	2013-02-04	2018-11-21	法商賽諾菲公司	胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
WO2015104311A1 (en)	2014-01-09	2015-07-16	Sanofi	Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
EP3091995B1 (en)	2014-01-09	2024-03-20	Sanofi	Stabilized pharmaceutical formulations of insulin aspart
SG11201604706TA (en)	2014-01-09	2016-07-28	Sanofi Sa	Stabilized pharmaceutical formulations of insulin aspart
TWI758239B (zh)	2014-12-12	2022-03-21	德商賽諾菲阿凡提斯德意志有限公司	甘精胰島素/利司那肽固定比率配製劑
TWI706779B (zh) *	2015-01-16	2020-10-11	德商賽諾菲阿凡提斯德意志有限公司	小兒第２型糖尿病病患之治療
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
ES2993282T3 (en) *	2018-07-23	2024-12-26	Lilly Co Eli	Method of using a gip/glp1 co-agonist for diabetes
US12465016B2 (en)	2019-12-19	2025-11-11	Allflex USA LLC	Vaccination identification button for electronic identification button tags to identify cattle as being inoculated against brucellosis, and kits and methods related thereto

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
AU2005271526B2 (en) *	2004-08-03	2011-12-08	Emisphere Technologies, Inc.	Antidiabetic oral insulin-biguanide combination
CN101291685A (zh) *	2005-08-19	2008-10-22	安米林药品公司	治疗糖尿病和降低体重的毒蜥外泌肽
CA2660835A1 (en) *	2006-08-17	2008-02-21	Amylin Pharmaceuticals, Inc.	Dpp-iv resistant gip hybrid polypeptides with selectable propperties
MX2011008416A (es) *	2009-02-13	2011-09-08	Boehringer Ingelheim Int	Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
PL2324853T3 (pl)	2009-11-13	2016-01-29	Sanofi Aventis Deutschland	Liksysenatyd jako dodatek do metforminy w leczeniu cukrzycy typu 2
US20110118178A1 (en) *	2009-11-13	2011-05-19	Sanofi-Aventis Deutschland Gmbh	Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
US20110118180A1 (en) *	2009-11-13	2011-05-19	Sanofi-Aventis Deutschland Gmbh	Method of treatment of diabetes type 2 comprising add-on therapy to metformin

2012
- 2012-05-11 BR BR112013029062A patent/BR112013029062A2/pt not_active Application Discontinuation
- 2012-05-11 HR HRP20151369TT patent/HRP20151369T1/hr unknown
- 2012-05-11 WO PCT/EP2012/058747 patent/WO2012156298A1/en not_active Ceased
- 2012-05-11 PL PL12723132T patent/PL2707017T3/pl unknown
- 2012-05-11 AU AU2012257849A patent/AU2012257849B2/en active Active
- 2012-05-11 MX MX2013013307A patent/MX362527B/es active IP Right Grant
- 2012-05-11 EP EP12723132.2A patent/EP2707017B1/en not_active Revoked
- 2012-05-11 JP JP2014509752A patent/JP6442284B2/ja active Active
- 2012-05-11 CA CA2835259A patent/CA2835259C/en active Active
- 2012-05-11 CN CN201711058028.0A patent/CN107693782A/zh active Pending
- 2012-05-11 KR KR1020137033310A patent/KR20140043755A/ko not_active Ceased
- 2012-05-11 PT PT127231322T patent/PT2707017E/pt unknown
- 2012-05-11 ES ES12723132.2T patent/ES2556466T3/es active Active
- 2012-05-11 US US13/469,633 patent/US20130065828A1/en not_active Abandoned
- 2012-05-11 SI SI201230377T patent/SI2707017T1/sl unknown
- 2012-05-11 RU RU2013155474A patent/RU2623023C2/ru active
- 2012-05-11 DK DK12723132.2T patent/DK2707017T3/en active
- 2012-05-11 HU HUE12723132A patent/HUE028459T2/en unknown
- 2012-05-11 CN CN201280034737.4A patent/CN103841988A/zh active Pending
2015
- 2015-12-15 CY CY20151101144T patent/CY1117250T1/el unknown
2018
- 2018-07-20 JP JP2018136356A patent/JP6676108B2/ja active Active

Also Published As

Publication number	Publication date
US20130065828A1 (en)	2013-03-14
JP2014514356A (ja)	2014-06-19
MX2013013307A (es)	2014-03-12
JP6676108B2 (ja)	2020-04-08
HRP20151369T1 (hr)	2016-01-15
CA2835259C (en)	2020-01-07
CA2835259A1 (en)	2012-11-22
CN103841988A (zh)	2014-06-04
BR112013029062A2 (pt)	2016-11-29
MX362527B (es)	2019-01-23
KR20140043755A (ko)	2014-04-10
EP2707017A1 (en)	2014-03-19
JP6442284B2 (ja)	2018-12-19
CY1117250T1 (el)	2017-04-05
WO2012156298A1 (en)	2012-11-22
CN107693782A (zh)	2018-02-16
RU2623023C2 (ru)	2017-06-21
ES2556466T3 (es)	2016-01-18
AU2012257849B2 (en)	2017-03-30
PT2707017E (pt)	2016-01-12
EP2707017B1 (en)	2015-09-16
SI2707017T1 (sl)	2016-01-29
HUE028459T2 (en)	2016-12-28
RU2013155474A (ru)	2015-06-20
DK2707017T3 (en)	2016-01-04
HK1194307A1 (en)	2014-10-17
JP2018184441A (ja)	2018-11-22

Publication	Publication Date	Title
SI2707017T1 (sl)	2016-01-29	Liksisenatid in metformin za zdravljenje sladkorne bolezni tipa 2
IL232251A0 (en)	2014-06-30	Protocol for the treatment of type 2 diabetes
ZA201403795B (en)	2016-01-27	Formulations for the treatment of diabetes
IL252699A0 (en)	2017-07-31	Use of lequinimod to treat multiple sclerosis
SI3495380T1 (sl)	2022-08-31	Ko-agonisti glukagona in GLP-1 za zdravljenje debelosti
PL2683395T3 (pl)	2019-04-30	Zastosowanie małych dawek il-2 do leczenia cukrzycy typu 1
IL220889A0 (en)	2012-09-24	Methods of treating diabetes with dll4 antagonists
IL223289A0 (en)	2013-02-03	Treatment of type 2 diabetes
AP2013007179A0 (en)	2013-10-31	Glycoside derivatives and their uses for the treatment of diabetes
EP2867239A4 (en)	2015-12-23	OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
HUE038787T2 (hu)	2018-11-28	Tripeptid készítmények és alkalmazásuk diabétesz kezelésére
SG11201408717XA (en)	2015-02-27	Stem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus
EP2774917A4 (en)	2015-05-06	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
ZA201408065B (en)	2016-04-28	Compositions and methods for the treatment of diabetes
PH12014501052A1 (en)	2014-06-30	Methods and compositions for the treatment of diabetes and related symptoms
EP2402342A4 (en)	2012-09-19	PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES
ZA201404738B (en)	2016-10-26	Treatment of type i and type ii diabetes
EP2680846A4 (en)	2014-08-06	USE OF N- (4-METHOXYPHENYL) -1-PHENYL-1H-PYRAZOL-3-AMINE AND COMPOUNDS ASSOCIATED THEREWITH
GB0919603D0 (en)	2009-12-23	Use of thymosin beta-4 for treatment of type II diabetes
EG27140A (en)	2015-08-09	Preparation and characterization of metformin as insulin resistant reducing agents for type ii diabetes
PT2717872T (pt)	2016-07-11	Combinação sinérgica para o tratamento da diabetes mellitus tipo 2
IL232294A0 (en)	2014-06-30	Preparations for the treatment of diabetes